BMS’s Baraclude increase market share

Published: 2011-02-18 06:56:00

Updated: 2011-02-18 06:56:00

The US based Bristol Myers Squibb’s Baraclude (entecavir) for treatment of hepatitis B accounted for about 50 percent of the sector’s domestic sales last year, an industry report showed yesterday.

Just within to two years of launch, Baraclude recorded 10 billion won in January, up 74.9 percent...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK